阿霉素
药物输送
PLGA公司
脑癌
胶质母细胞瘤
医学
靶向给药
鼻腔给药
癌症
癌症研究
药理学
胶质瘤
癌细胞
紫杉醇
化疗
药品
化学
纳米颗粒
内科学
纳米技术
材料科学
有机化学
作者
Kunho Chung,Irfan Ullah,Nahyeon Kim,Jaeyeoung Lim,Jung-Ah Shin,Sangah Clara Lee,Sang‐Min Jeon,Sun Hwa Kim,Priti Kumar,Sang‐Kyung Lee
标识
DOI:10.1080/1061186x.2019.1706095
摘要
Glioblastoma multiforme (GBM) is the most aggressive form of brain tumour and treatment is very challenging. Despite the recent advances in drug delivery systems, various approaches that allow sufficient deposition of anti-cancer drugs within the brain remain unsuccessful due to limited drug delivery throughout the brain. In this study, we utilised an intranasal (IN) approach to allow delivery of anti-cancer drug, encapsulated in PLGA nanoparticles (NPs). PLGA NPs were modified with the RGD ligand to enable Avβ3 expressing tumour-specific delivery. IN delivery of RGD-conjugated-doxorubicin (DOX)-loaded-PLGA-nanoparticles (RGD-DOX-NP) showed cancer-specific delivery of NP and inhibition of brain tumour growth compared to the free-DOX or non-modified DOX-NP in the C6-implanted GBM model. Further, IN treatment with RGD-DOX-NP induces apoptosis in the tumour region without affecting normal brain cells. Our study provides therapeutic evidence to treat GBM using a non-invasive IN approach, which may further be translated to other brain-associated diseases.
科研通智能强力驱动
Strongly Powered by AbleSci AI